Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (4): 628-631. doi: 10.19723/j.issn.1671-167X.2019.04.005

Previous Articles     Next Articles

Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery

Qi TANG,Rong-cheng LIN,Lin YAO,Zheng ZHANG,Han HAO,Cui-jian ZHANG,Lin CAI,Xue-song LI,Zhi-song HE(),Li-qun ZHOU()   

  1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University, Beijing 100034, China
  • Received:2019-03-06 Online:2019-08-18 Published:2019-09-03
  • Contact: Zhi-song HE,Li-qun ZHOU E-mail:wyj7074@sohu.com;zhoulqmail@china.com

Abstract:

Objective: To evaluate the clinicopathologic features and potential prognostic predictors of locally recurrent renal cell carcinoma patients after initial surgery.Methods: Authors retrospectively analyzed data extracted from 81 patients who were treated for postoperative locally recurrence of renal cell carcinoma from January 2006 to June 2016 in the Department of Urology, Peking University First Hospital. Postoperative locally recurrence of renal cell carcinoma was defined as disease recurring in the remnant kidney, renal fossa, adjacent abdomen, ipsilateral adrenal and retroperitoneal lymph nodes.Results: In the study, 81 patients were finally included, of whom 43 were initially treated in our hospital and 38 were initially treat in other centers. Partial nephrectomy (PN) was performed for 38 cases (26 in our hospital and 12 in other hospitals) as initial treatment and radical nephrectomy (RN) was conducted for the remnant 43 cases (17 in our hospital and 26 in other hospitals). Overall median recurrence time was 26 months (range: 3-164 months), in which 26 months (range: 3-55 months) for PN cases and 30 months (range: 4-164 months) for RN cases (P=0.009). Sixty-nine patients had single site recurrence, including remnant kidney (n=29), renal fossa (n=20), abdomen (n=4), ipsilateral lymph nodes (n=5), ipsilateral adrenal (n=11), while 12 patients had multiple sites recurrence. Seventy-eight patients were managed by complete surgical resection, while three patients were managed by radiofrequency ablation. Postoperative pathological diagnoses included clear cell carcinoma (n=72), papi-llary renal cell carcinoma (n=8, 7 cases with type 1, 1 case with type 2) and Xp11 translocation/TFE3 gene fusion renal cell carcinoma (n=1). Complete pathologic information of the initial surgery could be extracted from 43 patients who were initially treated in our hospital. Seventeen patients with initial radical nephrectomy were staged as T1a (n=4), T1b (n=2), T2a (n=1), T3a (n=8), and T3b (n=2). Twenty-six patients with initial partial nephrectomy were staged as T1a (n=18), T1b (n=7), and T3a (n=1). For PN cohort, the patients with T1a stage disease had longer median recurrence time than those with beyond T1a stage disease, and the difference was significant (29 months vs. 18 months, P=0.041). At the end of the follow-up, 58 patients were alive, 4 died and 19 lost the follow-up. Overall, 3-year and 5-year disease free survival rates were 81.9%, and 53.6%, respectively.Conclusion: The present research reported a large-scale single central experience of locally recurrent renal cell carcinoma. The recurrence time of the PN group is shorter than that of the RN group. For patients after PN surgery, median recurrence time is longer for patients with T1a stage tumor when compared with those with stage beyond T1a. Patients can obtain relative long-term survival after complete secondary surgery resection.

Key words: Renal cell carcinoma, Tumor recurrence, Surgical resection

CLC Number: 

  • R737.11

Figure 1

Comparison of the time to recurrence after initial partial nephrectomy an radical nephrectomy"

Figure 2

Comparison of the time to recurrence between patients with T1a stage and beyond T1a stage after initial partial nephrectomy"

[1] Siegel R, Miller K, Jemal A . Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30.
[2] Kuusk T , Grivas N, de Bruijn R, et al. The current management of renal cell carcinoma[J]. Minerva Med, 2017,108(4):357-369.
[3] Margulis V, Mcdonald M, Tamboli P , et al. Predictors of oncolo-gical outcome after resection of locally recurrent renal cell carcinoma[J]. J Urol, 2009,181(5):2044-2051.
[4] 杨洋, 肖云翔, 周利群 , 等. 手术治疗肾癌根治术后孤立局部复发病灶的长期预后分析[J]. 北京大学学报(医学版), 2014,46(4):528-531.
[5] Lane BR, Gill IS . 5-year outcomes of laparoscopic partial nephrectomy[J]. J Urol, 2007,177(1):70-74.
[6] Campbell SC, Novick AC . Management of local recurrence fol-lowing radical nephrectomy or partial nephrectomy[J]. Urol Clin North Am, 1994,21(4):593-599.
[7] Bigot P, Hetet JF, Bernhard JC , et al. Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes[J]. Clin Genitourin Cancer, 2014,12(1):e19-e27.
[8] Mir MC, Derweesh I, Porpiglia F , et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies[J]. Eur Urol, 2017,71(4):606-617.
[9] Brookman-May S, May M, Shariat SF , et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)[J]. Eur Urol, 2013,64(3):472-477.
[10] Nakano E, Fujioka H, Matsuda M , et al. Late recurrence of renal cell carcinoma after nephrectomy[J]. Eur Urol, 1984,10(5):347-349.
[11] Miyao N, Naito S, Ozono S , et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer[J]. Urology, 2011,77(2):379-384.
[12] Park YH, Baik KD, Lee YJ , et al. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis[J]. BJU Int, 2012,110(11 Pt B):E553-E558.
[13] Lee BH, Feifer A, Feuerstein MA , et al. Validation of a post-operative nomogram predicting recurrence in patients with conventional clear cell renal cell carcinoma[J]. Eur Urol Focus, 2018,4(1):100-105.
[14] Itano NB, Blute ML, Spotts B , et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy[J]. J Urol, 2000,164(2):322-325.
[15] Yohannan J, Feng T, Berkowitz J , et al. Laparoscopic resection of local recurrence after previous radical nephrectomy for clinically localized renal-cell carcinoma: perioperative outcomes and initial observations[J]. J Endourol, 2010,24(10):1609-1612.
[16] Ljungberg B, Albiges L, Abu-Ghanem Y , et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update[J]. Eur Urol, 2019,75(5):799-810.
[1] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[2] SUN Zheng-hui,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,YAN Ye,LIU Cheng,MA Lu-lin. Risk factors of renal sinus invasion in clinical T1 renal cell carcinoma patients undergoing nephrectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 659-664.
[3] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[4] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[5] HONG Peng,TIAN Xiao-jun,ZHAO Xiao-yu,YANG Fei-long,LIU Zhuo,LU Min,ZHAO Lei,MA Lu-lin. Bilateral papillary renal cell carcinoma following kidney transplantation: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 811-813.
[6] HAN Song-chen,HUANG Zi-xiong,LIU Hui-xin,XU Tao. Renal functional compensation after unilateral radical nephrectomy of renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 680-685.
[7] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[8] Li-wei LI,Zhuo LIU,Guo-liang WANG,Hua ZHANG,Wen CHEN,Jing MA,Li ZHANG,Wei HE,Lu-lin MA,Shu-min WANG. Comparison of various imaging in the diagnosis of renal cell carcinoma with inferior vena cava tumor thrombus combined with bland thrombus [J]. Journal of Peking University(Health Sciences), 2019, 51(4): 678-683.
[9] Xiao-peng ZHANG,Zi-xiong HUANG,Lu-ping YU,Xiao-wei ZHANG,Qing LI,Shi-jun LIU,Tao XU. Clinical and pathological analysis of small renal cell carcinoma [J]. Journal of Peking University(Health Sciences), 2019, 51(4): 623-627.
[10] HUANG Zi-xiong, DU Yi-qing, ZHANG Xiao-peng, LIU Shi-jun, XU Tao. Clinical and pathological analysis of renal cell carcinoma bone metastasis [J]. Journal of Peking University(Health Sciences), 2018, 50(5): 811-815.
[11] DING Zhen-shan,QIU Min,XU Zi-cheng,XIAO Ruo-tao,GE Li-yuan,MA Lu-lin. Clinicopathological analysis of patients with papillary renal cell carcinoma complicated by tumor thrombus [J]. Journal of Peking University(Health Sciences), 2018, 50(5): 805-810.
[12] ZENG Hong, RONG Xiao-ying, ZHANG Xiao-qing, GUO Xiang-yang. Application of intraoperative cell salvage combined with leukocyte depletion filter on radical nephrectomy for renal carcinoma with inferior vena cava tumor thrombus:2 case reports#br# [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 736-739.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 361 -364 .